Další formáty:
BibTeX
LaTeX
RIS
@article{1605051,
author = {Krejčí, Pavel},
article_location = {Waltham},
article_number = {13},
doi = {http://dx.doi.org/10.1056/NEJMc1910394},
keywords = {Achondroplasia; C-type natriuretic peptide},
language = {eng},
issn = {0028-4793},
journal = {New England Journal of Medicine},
title = {C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia},
url = {http://dx.doi.org/10.1056/NEJMc1910394},
volume = {381},
year = {2019}
}
TY - JOUR
ID - 1605051
AU - Krejčí, Pavel
PY - 2019
TI - C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia
JF - New England Journal of Medicine
VL - 381
IS - 13
SP - 1291
EP - 1291
PB - Massachussetts Medical Society
SN - 00284793
KW - Achondroplasia
KW - C-type natriuretic peptide
UR - http://dx.doi.org/10.1056/NEJMc1910394
L2 - http://dx.doi.org/10.1056/NEJMc1910394
N2 - Savarirayan et al. (July 4 issue)1 report increased skeletal growth in patients with achondroplasia (a common type of dwarfism caused by activating mutations in the tyrosine kinase fibroblast growth factor receptor 3 gene FGFR3) who received vosoritide, a stable analogue of C-type natriuretic peptide. Their study is a breakthrough in treatment for achondroplasia, and it offers an intriguing possibility of broader clinical applications.
ER -
KREJČÍ, Pavel. C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia. \textit{New England Journal of Medicine}. Waltham: Massachussetts Medical Society, 2019, roč.~381, č.~13, s.~1291. ISSN~0028-4793. Dostupné z: https://dx.doi.org/10.1056/NEJMc1910394.
|
